[
  {
    "ts": null,
    "headline": "FDA Extends Review of DNLI's Hunter Syndrome Drug by Three Months",
    "summary": "Denali Therapeutics faces an FDA review delay for its Hunter syndrome drug, pushing potential approval of tividenofusp alfa to April 2026.",
    "url": "https://finnhub.io/api/news?id=86325135d0ade3ea67b907dc9c9b3a434f1894b20226e88e764e16965f019705",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760444580,
      "headline": "FDA Extends Review of DNLI's Hunter Syndrome Drug by Three Months",
      "id": 137086448,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BIIB",
      "source": "Yahoo",
      "summary": "Denali Therapeutics faces an FDA review delay for its Hunter syndrome drug, pushing potential approval of tividenofusp alfa to April 2026.",
      "url": "https://finnhub.io/api/news?id=86325135d0ade3ea67b907dc9c9b3a434f1894b20226e88e764e16965f019705"
    }
  },
  {
    "ts": null,
    "headline": "1 Healthcare Stock to Research Further and 2 We Find Risky",
    "summary": "Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. But speed bumps such as inventory destockings have persisted in the wake of COVID-19, limiting growth. This has capped returns as the industry’s six-month gain of 8.6% has lagged the S&P 500’s 22.9% climb.",
    "url": "https://finnhub.io/api/news?id=76a94b44f60a66afa0c94d601551a8e4924ca352f779f40df076c43c7db81684",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760416553,
      "headline": "1 Healthcare Stock to Research Further and 2 We Find Risky",
      "id": 137086030,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BIIB",
      "source": "Yahoo",
      "summary": "Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. But speed bumps such as inventory destockings have persisted in the wake of COVID-19, limiting growth. This has capped returns as the industry’s six-month gain of 8.6% has lagged the S&P 500’s 22.9% climb.",
      "url": "https://finnhub.io/api/news?id=76a94b44f60a66afa0c94d601551a8e4924ca352f779f40df076c43c7db81684"
    }
  }
]